|
KMID : 0620920220540091401
|
|
Experimental & Molecular Medicine
2022 Volume.54 No. 9 p.1401 ~ p.1411
|
|
|
The resurrection of RIP kinase 1 as an early cell death checkpoint regulatorㅡa potential target for therapy in the necroptosis era
|
|
Ju Eun-Jin
Park Kyeong-Ah
Shen Han-Ming
Hur Gang-Min
|
|
|
Abstract
|
|
|
|
Receptor-interacting serine threonine protein kinase 1 (RIPK1) has emerged as a central molecular switch in controlling the balance between cell survival and cell death. The pro-survival role of RIPK1 in maintaining cell survival is achieved via its ability to induce NF-κB-dependent expression of anti-apoptotic genes. However, recent advances have identified the pro-death function of RIPK1: posttranslational modifications of RIPK1 in the tumor necrosis factor receptor 1 (TNFR1)-associated complex-I, in the cytosolic complex-IIb or in necrosomes regulate the cytotoxic potential of RIPK1, forming an early cell death checkpoint. Since the kinase activity of RIPK1 is indispensable in RIPK3- and MLKL-mediated necroptosis induction, while it is dispensable in apoptosis, a better understanding of this early cell death checkpoint via RIPK1 might lead to new insights into the molecular mechanisms controlling both apoptotic and necroptotic modes of cell death and help develop novel therapeutic approaches for cancer. Here, we present an emerging view of the regulatory mechanisms for RIPK1 activity, especially with respect to the early cell death checkpoint. We also discuss the impact of dysregulated RIPK1 activity in pathophysiological settings and highlight its therapeutic potential in treating human diseases.
|
|
|
KEYWORD
|
|
|
Apoptosis, Checkpoint signalling, Necroptosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|